COMP <GO>
IVVD vs ABOS // FREE CASH FLOW YIELD
Invivyd Inc. (NASDAQ) VS. Acumen Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IVVD 3
— ABOS 0
■ METRIC PARITY
LAST: $0.58 (-3.37%) • MKT CAP: $177.4M
fcf-yield
—
LAST: $0.21 (-90.82%) • MKT CAP: $165.6M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IVVD VS. ABOS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IVVD | ABOS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | IVVD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.2 | 20.3 | +15.90 | IVVD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $177.4M | $165.6M | $11.8M | IVVD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IVVD REV | ABOS REV | IVVD GROSS % | ABOS GROSS % | IVVD FCF | ABOS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $53.4M | $0 | — | — | -$58.3M | -$115.5M |
| FY 2024 | $25.4M | $0 | — | — | -$170.6M | -$86.2M |
| FY 2023 | $0 | $0 | — | — | -$173.2M | -$43.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IVVD // BETA —
ABOS // BETA —